In this issue:
Managing dupilumab-related ocular surface disorders
Biologic switching in psoriasis
IL-17 vs IL-23 inhibitors and systemic inflammation in psoriasis
Cardiometabolic safety of dupilumab in atopic dermatitis
Biologics and risk of inflammatory arthritis in psoriasis
Cemiplimab for advanced cutaneous squamous cell carcinoma
Risk of fungal infection in psoriasis patients receiving biologics
Dazukibart, IFNβ-specific monoclonal antibody, for dermatomyositis
Upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis
Drug survival in paediatric atopic dermatitis
Please login below to download this issue (PDF)